Cavalier Daily1d
U.Va. student diagnosed with Meningococcal disease
Bonner said anyone exhibiting symptoms of the disease should make an appointment with Student Health and Wellness for ...
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week (UPDATED)
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
STAT14d
Pharmalittle: We’re reading about the impact of HHS firings, a GSK vaccine approval, and more
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
HealthDay on MSN6d
FDA Approves More Broadly Protective Meningococcal Vaccine
The US FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease.
Healio14d
FDA approves GSK’s pentavalent meningococcal vaccine
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...
BioPharma Dive14d
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
PharmiWeb14d
Meningococcal Vaccine Market Projected to Reach USD 9014 Million by 2034 at a 8.6% of CAGR
Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...
Medscape16d
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration
Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age ...
Benzinga.com13d
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...